NEWPORT BEACH, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today reported financial results for the first quarter ended March 31, 2024. Elevai Labs CEO, Jordan R. Plews, PhD stated, "This quarter, Elevai Labs has demonstrated remarkable year-over-year revenue growth while significantly improving our gross margin, reflecting our commitment to optimizing production and stringent cost management. We remain focused on sustainable growth while enhancing our operational efficiencies and continuing to invest in innovation. These results underscore our adaptability and strategic foresight in meeting market demands." Financial Results for the Three Months Ended March 31, 2024 Revenue increased to $614,563 for the three months ended March 31, 2024, compared to $142,820 for the three months ended March 31, 2023 and $698,591 for the three months ended December 31, 2023, a 330.3% increase year-over-year and 12.0% decrease quarter-over-quarter. Gross margin of 72.5% for the three months ended ...